PLEU18029 / AALL1631 / Kazi (formerly Mullen)
Research Question:
Does the drug imatinib mesylate help treat patients with newly diagnosed leukemia
patients?
Basic Study Information
Purpose:
This randomized phase III trial studies how well imatinib mesylate works in combination
with two different chemotherapy regimens in treating patients with newly diagnosed
Philadelphia chromosome positive acute lymphoblastic leukemia (ALL). Imatinib mesylate
has been shown to improve outcomes in children and adolescents with Philadelphia chromosome
positive (Ph+) ALL when given with strong chemotherapy, but the combination has many
side effects. This trial is testing whether a different chemotherapy regimen may work
as well as the stronger one but have fewer side effects when given with imatinib.
The trial is also testing how well the combination of chemotherapy and imatinib works
in another group of patients with a type of ALL that is similar to Ph+ ALL. This type
of ALL is called "ABL-class fusion positive ALL", and because it is similar to Ph+
ALL, is thought it will respond well to the combination of agents used to treat Ph+
ALL.
Location: University of Rochester
Lead Researcher (Principal Investigator)
Lead Researcher:
Rafi Kazi
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search